DNA Methylation Analysis
Overview
DNA methylation is a key epigenetic mechanism involved in gene regulation. Leveraging this scientific foundation, our DNA Methylation Analysis Technology is being developed to enable early, accurate, and non-invasive cancer detection. This investigational approach aims to enhance diagnostic precision and contribute to improving the early identification and management of cancers.
A Strategic Partnership
Our advancements in DNA Methylation Analysis Technology are driven by a close collaboration with EG BioMed, a recognized innovator in cancer diagnostics research. This partnership integrates EG BioMed’s proprietary research and methodologies with YD Biopharma’s expertise in clinical development and future market distribution.
Demonstrated High Accuracy
Sensitivity:
Up to 99% in early-stage cancer detection in preclinical evaluations.
Specificity:
Designed to reduce false positives and support more reliable diagnostic assessments.
Cost-Effective and Scalable
A qPCR-based testing platform under development aims to offer an affordable solution while maintaining high analytical accuracy.
The scalable infrastructure is designed to support broader adoption across clinical research and future diagnostic applications.
Streamlined Workflow
User-friendly sample collection and analysis processes are being developed to minimize complexity for clinicians and laboratories.
Results will be accessible through the EG Biocloud Report System, supporting integration into clinical research and future diagnostic workflows.
Room Temperature Stability
Samples are designed to be stably stored and transported at room temperature for up to 14 days under controlled conditions, aiming to simplify logistics and reduce operational costs.
Taiwan
With 10.6% diabetes prevalence, 2.48 million patients, and rising pancreatic cancer risks, Taiwan presents a 10 million-test annual market, creating strong opportunities for strategic partnerships and innovation.
United States
Targeting a potential market of 30 million tests annually with strategic lab partnerships and CAP certification.
Worldwide
Positioned to lead the USD 2.37 billion pancreatic cancer diagnostics market, projected to grow at a 6.53% CAGR by 2030.
Market Potential
YD Biopharma’s Role
Exclusive Commercialization Rights
YD Biopharma is the sole distributor of EG BioMed's DNA Methylation Analysis technology, ensuring global access to these groundbreaking solutions.
Integration into Clinical Practice
We leverage our extensive network and regulatory expertise to bring EG BioMed's innovations to hospitals, clinics, and laboratories worldwide.
Expanding Market Reach
YD Biopharma is focused on expanding access to EG BioMed’s technology. With a strong position in the market, we are poised to align with regulatory trends and growing demand. Our approach ensures global accessibility, enabling hospitals and specialized research facilities to integrate this technology seamlessly.
Cutting-Edge Approach
Our DNA Methylation Analysis technology, powered by cfDNA methylation and qPCR, surpasses traditional methods like CA19-9 and microRNA analysis. Unlike competitors relying on fragile RNA or high-cost NGS platforms, our approach ensures:
Greater stability and repeatability
Faster reporting times
Lower costs, making it accessible to a broader population
